A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

René Carvajal; Carmen Tur; Xavier Martínez-Gómez; Luca Bollo; Juliana Esperalba; Marta Rodriguez; Agustín Pappolla; Alvaro Cobo-Calvo; Pere Carbonell; Blanca Borras-Bemejo; Jordi Río; Joaquín Castilló; Nathane Braga; Neus Mongay-Ochoa; José Ángel Rodrigo-Pendás; Ángela Vidal-Jordana; Georgina Arrambide; Breogán Rodríguez-Acevedo; Ana Zabalza; Luciana Midaglia; Ingrid Galán; Manuel Comabella; Jaume Sastre-Garriga; Xavier Montalban; Mar Tintoré; Susana Otero-Romero

doi:10.1177/13524585231200303

A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

René Carvajal, Carmen Tur, Xavier Martínez-Gómez, Luca Bollo, Juliana Esperalba, Marta Rodriguez, Agustín Pappolla, Alvaro Cobo-Calvo, Pere Carbonell, Blanca Borras-Bemejo, Jordi Río, Joaquín Castilló, Nathane Braga, Neus Mongay-Ochoa, José Ángel Rodrigo-Pendás, Ángela Vidal-Jordana, Georgina Arrambide, Breogán Rodríguez-Acevedo, Ana Zabalza, Luciana MidagliaIngrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Xavier Montalban, Mar Tintoré, Susana Otero-Romero

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

6 Cites (Scopus)

Resum

BACKGROUND: Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized.

OBJECTIVES: To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS.

METHODS: Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies.

RESULTS: Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66.7% (95% confidence interval (CI): 53.3-78.3) versus 97.2% (95% CI: 85.5-99.9) in the SIS (p
CONCLUSION: An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid

Idioma original	Anglès
Número d’article	13524585231200303
Pàgines (de-a)	1841-1848
Nombre de pàgines	8
Revista	Multiple sclerosis (Houndmills, Basingstoke, England)
Volum	29
Número	14
Data online anticipada	20 de set. 2023
DOIs	https://doi.org/10.1177/13524585231200303
Estat de la publicació	Publicada - de des. 2023

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1177/13524585231200303Llicència: Creative Commons Reconeixement No Comercial

Altres arxius i enllaços

Com citar-ho

Carvajal, R., Tur, C., Martínez-Gómez, X., Bollo, L., Esperalba, J., Rodriguez, M., Pappolla, A., Cobo-Calvo, A., Carbonell, P., Borras-Bemejo, B., Río, J., Castilló, J., Braga, N., Mongay-Ochoa, N., Rodrigo-Pendás, J. Á., Vidal-Jordana, Á., Arrambide, G., Rodríguez-Acevedo, B., Zabalza, A., ... Otero-Romero, S. (2023). A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 29(14), 1841-1848. Article 13524585231200303. https://doi.org/10.1177/13524585231200303

@article{317544c96a3f46aab83ce40b152fa0f2,

title = "A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients",

abstract = "Background: Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized. Objectives: To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS. Methods: Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies. Results: Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66.7% (95% confidence interval (CI): 53.3–78.3) versus 97.2% (95% CI: 85.5–99.9) in the SIS (p < 0.001). For the seroprotected patients, GMTs were similar for both schemes. Conclusion: An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid immunization.",

keywords = "Disease-modifying therapy, Infections, Live attenuated vaccine, Multiple sclerosis, Vaccination",

author = "Ren{\'e} Carvajal and Carmen Tur and Xavier Mart{\'i}nez-G{\'o}mez and Luca Bollo and Juliana Esperalba and Marta Rodriguez and Agust{\'i}n Pappolla and Alvaro Cobo-Calvo and Pere Carbonell and Blanca Borras-Bemejo and Jordi R{\'i}o and Joaqu{\'i}n Castill{\'o} and Nathane Braga and Neus Mongay-Ochoa and Rodrigo-Pend{\'a}s, {Jos{\'e} {\'A}ngel} and {\'A}ngela Vidal-Jordana and Georgina Arrambide and Breog{\'a}n Rodr{\'i}guez-Acevedo and Ana Zabalza and Luciana Midaglia and Ingrid Gal{\'a}n and Manuel Comabella and Jaume Sastre-Garriga and Xavier Montalban and Mar Tintor{\'e} and Susana Otero-Romero",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2023.",

year = "2023",

month = dec,

doi = "10.1177/13524585231200303",

language = "English",

volume = "29",

pages = "1841--1848",

journal = "Multiple sclerosis (Houndmills, Basingstoke, England)",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "14",

}

Carvajal, R, Tur, C, Martínez-Gómez, X, Bollo, L, Esperalba, J, Rodriguez, M, Pappolla, A, Cobo-Calvo, A, Carbonell, P, Borras-Bemejo, B, Río, J, Castilló, J, Braga, N, Mongay-Ochoa, N, Rodrigo-Pendás, JÁ, Vidal-Jordana, Á, Arrambide, G, Rodríguez-Acevedo, B, Zabalza, A, Midaglia, L, Galán, I, Comabella, M, Sastre-Garriga, J, Montalban, X, Tintoré, M & Otero-Romero, S 2023, 'A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients', Multiple sclerosis (Houndmills, Basingstoke, England), vol. 29, núm. 14, 13524585231200303, pàg. 1841-1848. https://doi.org/10.1177/13524585231200303

A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients. / Carvajal, René; Tur, Carmen; Martínez-Gómez, Xavier et al.
In: Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 14, 13524585231200303, 12.2023, pàg. 1841-1848.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

AU - Carvajal, René

AU - Tur, Carmen

AU - Martínez-Gómez, Xavier

AU - Bollo, Luca

AU - Esperalba, Juliana

AU - Rodriguez, Marta

AU - Pappolla, Agustín

AU - Cobo-Calvo, Alvaro

AU - Carbonell, Pere

AU - Borras-Bemejo, Blanca

AU - Río, Jordi

AU - Castilló, Joaquín

AU - Braga, Nathane

AU - Mongay-Ochoa, Neus

AU - Rodrigo-Pendás, José Ángel

AU - Vidal-Jordana, Ángela

AU - Arrambide, Georgina

AU - Rodríguez-Acevedo, Breogán

AU - Zabalza, Ana

AU - Midaglia, Luciana

AU - Galán, Ingrid

AU - Comabella, Manuel

AU - Sastre-Garriga, Jaume

AU - Montalban, Xavier

AU - Tintoré, Mar

AU - Otero-Romero, Susana

PY - 2023/12

Y1 - 2023/12

N2 - Background: Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized. Objectives: To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS. Methods: Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies. Results: Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66.7% (95% confidence interval (CI): 53.3–78.3) versus 97.2% (95% CI: 85.5–99.9) in the SIS (p < 0.001). For the seroprotected patients, GMTs were similar for both schemes. Conclusion: An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid immunization.

AB - Background: Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized. Objectives: To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS. Methods: Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies. Results: Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66.7% (95% confidence interval (CI): 53.3–78.3) versus 97.2% (95% CI: 85.5–99.9) in the SIS (p < 0.001). For the seroprotected patients, GMTs were similar for both schemes. Conclusion: An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid immunization.

KW - Disease-modifying therapy

KW - Infections

KW - Live attenuated vaccine

KW - Multiple sclerosis

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85173435995&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/669d3e4d-2042-3e69-ad6e-95148d452cfe/

U2 - 10.1177/13524585231200303

DO - 10.1177/13524585231200303

M3 - Article

C2 - 37728389

SN - 1352-4585

VL - 29

SP - 1841

EP - 1848

JO - Multiple sclerosis (Houndmills, Basingstoke, England)

JF - Multiple sclerosis (Houndmills, Basingstoke, England)

IS - 14

M1 - 13524585231200303

ER -

Carvajal R, Tur C, Martínez-Gómez X, Bollo L, Esperalba J, Rodriguez M et al. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England). 2023 des.;29(14):1841-1848. 13524585231200303. Epub 2023 set. 20. doi: 10.1177/13524585231200303

A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho